Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost

Feldman, Steven R.; Garton, Rachel; Averett, William; Balkrishnan, Rajesh; Vallee, Jeffrey A.

doi:10.1517/eoph.4.9.1525.21059

Cited by 7 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most evaluations were cost‐effectiveness analyses (43 of 71 comparisons, 22 of 37 papers) or cost–utility analyses (25 of 71 comparisons, 17 of 37 papers) . Three cost–benefit comparisons met inclusion criteria .…”

Section: Resultsmentioning

confidence: 99%

“…Three cost–benefit comparisons met inclusion criteria . Most papers (57 of 71 comparisons, 30 of 37 papers) reported modelling studies synthesizing data from several sources. Four articles (seven of 71 comparisons) were randomized controlled trial (RCT) based and three articles (seven of 71 comparisons) used observational designs …”

Section: Resultsmentioning

confidence: 99%

“…Comparisons of more severe forms of psoriasis were more common (38 of 71 comparisons, 23 of 37 papers) than milder disease (19 of 71 comparisons, eight of 37 articles) . Seven articles (14 of 71 comparisons) either did not specify disease severity or reported a mild to severe range.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Psoriasis treatment and management - a systematic review of full economic evaluations

et al. 2015

View full text Add to dashboard Cite

The economic evidence is dominated by comparisons of interventions to placebo, with implicit comparisons of different therapies. There is a lack of evaluations of service model innovations to deliver complex packages of care for psoriasis. Primary and secondary integrated clinical and economic research is needed to address the limitations and to identify patient preferences and barriers/facilitators to treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis treatment and management - a systematic review of full economic evaluations

et al. 2015

View full text Add to dashboard Cite

show abstract

“…47 Prof. Ferguson felt that TL01 was probably the first choice for chronic plaque psoriasis but said that, in his experience, some patients do better with PUVA in terms of both time of clearance and remission time, and urged people not to throw away their PUVA cabinets. In a cost-efficacy study, Feldman et al 48 considered that UVB phototherapy appears to be the best first-line agent for the control of psoriasis, with methotrexate, PUVA and the biological treatments, second-line agents, the choice of which requires considerable patient input and physician judgement. 48 Nijsten and Stern 49 revealed that the nonmelanoma skin cancer risk for PUVA patients is high for patients with high levels of PUVA exposure.…”

Section: Dermatopathologymentioning

confidence: 99%

“…In a cost-efficacy study, Feldman et al 48 considered that UVB phototherapy appears to be the best first-line agent for the control of psoriasis, with methotrexate, PUVA and the biological treatments, second-line agents, the choice of which requires considerable patient input and physician judgement. 48 Nijsten and Stern 49 revealed that the nonmelanoma skin cancer risk for PUVA patients is high for patients with high levels of PUVA exposure. For at least 15 years after stopping PUVA in psoriasis, the risk to patients of developing a SCC is not reduced.…”

Section: Dermatopathologymentioning

confidence: 99%

Updates from the British Association of Dermatologists 84th Annual Meeting, 6-9 July 2004, Belfast, U.K.

Eedy

English

2005

British Journal of Dermatology

View full text Add to dashboard Cite

Herein is a synopsis of the main research and clinical findings presented at the British Association of Dermatologists meeting held during 6-9 July 2004, in Belfast, U.K. The conference highlighted the progress that has been made in understanding the increasing biological, epidemiological and therapeutic advances that have been made recently in the field of dermatology. The authors highlight the more important advances or summaries, but this is not meant as a substitute for reading the conference proceedings and related references quoted in this article.

show abstract

Recent Trends in Systemic Psoriasis Treatment Costs

Beyer

Wolverton²

2010

Arch Dermatol

View full text Add to dashboard Cite

To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index-Urban since 2000.Design: A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index-Urban values.Setting: The United States.Main Outcome Measures: Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index-Urban values (equivalent to inflation).Results: Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66% (range, −24% to ϩ316%); thus, costs of several brandname psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs.Conclusions: Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.

show abstract

Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost

Cited by 7 publications

References 0 publications

Psoriasis treatment and management - a systematic review of full economic evaluations

Psoriasis treatment and management - a systematic review of full economic evaluations

Updates from the British Association of Dermatologists 84th Annual Meeting, 6-9 July 2004, Belfast, U.K.

Recent Trends in Systemic Psoriasis Treatment Costs

Contact Info

Product

Resources

About